These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6666 related articles for article (PubMed ID: 12749752)

  • 21. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
    Helfand SC; Hank JA; Gan J; Sondel PM
    Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of endogenous augmentation of antiganglioside IgM in cancer patients: potential tool for early detection and management of cancer therapy.
    Ravindranath MH; Muthugounder S; Hannah MR; Morton DL
    Ann N Y Acad Sci; 2007 Jun; 1107():212-22. PubMed ID: 17804549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gangliosides as Signaling Regulators in Cancer.
    Sasaki N; Toyoda M; Ishiwata T
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34064863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gangliosides as carbohydrate antigens associated with cancer and their possible use in tumor immunotherapy].
    Horwacik I
    Przegl Lek; 2004; 61 Suppl 2():14-9. PubMed ID: 15686040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ganglioside as a Therapy Target in Various Types of Cancer.
    Qamsari ES; Nourazarian A; Bagheri S; Motallebnezhad M
    Asian Pac J Cancer Prev; 2016; 17(4):1643-7. PubMed ID: 27221833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
    Zhang H; Zhang S; Cheung NK; Ragupathi G; Livingston PO
    Cancer Res; 1998 Jul; 58(13):2844-9. PubMed ID: 9661900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gangliosides as immunomodulators.
    Potapenko M; Shurin GV; de León J
    Adv Exp Med Biol; 2007; 601():195-203. PubMed ID: 17713006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GD2-targeted immunotherapy and radioimmunotherapy.
    Dobrenkov K; Cheung NK
    Semin Oncol; 2014 Oct; 41(5):589-612. PubMed ID: 25440605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of tumor-associated gangliosides in cancer progression.
    Birklé S; Zeng G; Gao L; Yu RK; Aubry J
    Biochimie; 2003; 85(3-4):455-63. PubMed ID: 12770784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration.
    Vyas AA; Patel HV; Fromholt SE; Heffer-Lauc M; Vyas KA; Dang J; Schachner M; Schnaar RL
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8412-7. PubMed ID: 12060784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expanding role of immunotherapy.
    Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
    Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant ganglioside composition in glioblastoma multiforme and peritumoral tissue: A mass spectrometry characterization.
    Fabris D; Rožman M; Sajko T; Vukelić Ž
    Biochimie; 2017 Jun; 137():56-68. PubMed ID: 28286312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of cellular ganglioside depletion on tumor formation.
    Deng W; Li R; Ladisch S
    J Natl Cancer Inst; 2000 Jun; 92(11):912-7. PubMed ID: 10841826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ganglioside GD1alpha functions in the adhesion of metastatic tumor cells to endothelial cells of the target tissue.
    Taki T; Ishikawa D; Ogura M; Nakajima M; Handa S
    Cancer Res; 1997 May; 57(10):1882-8. PubMed ID: 9157980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement as effector system in cancer immunotherapy.
    Macor P; Tedesco F
    Immunol Lett; 2007 Jul; 111(1):6-13. PubMed ID: 17572509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Gangliosides and cancer].
    Dumontet C; Portoukalian J
    Bull Cancer; 1991; 78(9):789-99. PubMed ID: 1751830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycosphingolipid expression in solid tumours and transformed cell lines.
    Berra B; Colombo I; Monteggia E; Montorfano G; Moretti S; Rapelli S; Sottocornola E
    Indian J Biochem Biophys; 1997; 34(1-2):170-7. PubMed ID: 9343946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
    López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
    Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 334.